|MIGAL – Galilee Research Institute||CEO||Israel|
Artificial intelligence to speed up drug discovery: The revolutionary road to advancing innovation
- Avishai Levy, CEO – Galilee Research Institute (Ending soon, new ventures on their way)Mr Levy is an experienced manager and a business development professional specializing in managing technology companies In the areas of: translational research, drug discovery, Healthcare IT (Digital health) and agrotechnology. Since 2013 he serves as the General Manager of The Galilee Research Institute (“Migal”) a 300+ employee’s multidisciplinary applied research Institute. In the years before Mr. levy focused on the development of several novel technologies in biopharma and HLS as well as providing external business development and IP services to R&D companies. From 2004 – 2011 Mr. Levy was CEO and President of Proteologics Inc., Delaware, a US holding company and CEO of Rehovot, Israel Proteologics Ltd, a publicly traded drug discovery company who among its shareholders, at the time, were Teva Pharmaceutical Industries and GSK. He serves as board member in several ventures including Immpact Bio which develops novel CART discovery platform and Saturas Ag which develops a novel AI supported sensors. In addition to his diverse business duties Mr. Levy is a lecturer at the Biotechnology program of the Agriculture faculty of the Hebrew University. Mr. Levy academic record include Executive LL.M from the Northwestern law school Chicago IL, an M.Sc. (Genetics) and LL.B degrees from Tel Aviv University and BSc, Agr. from the Hebrew University of Jerusalem, He is also a certified electronic and algorithm technician and is a member of the Israeli bar specializing in IP and commercial law.